Pharmaceutical Executive-11-01-2021

While pharma has reached new heights in vaccine development, many questions remain around the lasting effects of COVID and how future therapies can curb them.

It wasn’t long before sales reps realized they needed a new strategy to keep prospect pools flowing—18 months later, a mix of in-person and virtual meetings with healthcare professionals is emerging as the preferred approach moving forward.

Pharma organizations have long been vigilant in protecting their intellectual property and financial information, but the disruption of COVID-19 has seen an expansion of the ‘cyberattack surface.’

How an increased focus on people has helped companies survive the pandemic.

Moderna Chief Medical Officer Paul Burton looks to build on culture of innovation and speed to advance COVID-19 vaccine and develop new therapies based on its novel mRNA platform, spreading hope to patients around the world.

Regulatory headwinds are poised to ease as new year approaches.

New age of drug marketing must consider market access.

Traditionally difficult in pharma, data science recruitment witnessed a sharp drop-off at the beginning of the pandemic, but interest has since bounced back to unexpected levels.

Building and maintaining relationships can lead to better decisions.

Committee struggles to find a common treatment approach.

Looking back at 2015–2018.

Recognizing leadership in pharma.

Click the title above for a link to open the Pharmaceutical Executive November 2021 issue in an interactive PDF format.

Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.

Changes prompt collaboration and improved quality management.